Q4 2024 Deck Updates_ Part 2

Question 1

What new imaging agents were added to the prostate cancer imaging landscape?

Answer 1

68Ga-AZ-093, 18F-GRPR, HRS-9815, LNTH-2401, 68Ga-NeoB, 61Cu-NODAGA-PSMA-I&T

These agents are from various pharmaceutical companies including Five Eleven Pharma, Fuzionaire Theranostics, Hengrui, Lantheus, Novartis, and Nuclidium AG.

Question 2

Which imaging agents had their development timelines modified due to uncertainty?

Answer 2

18F-CTT1057, 18F-PSMA-1007

These modifications were made to reflect uncertain development and commercialization timelines.

Question 3

What was the reason for the reduced development timeline of 64Cu-PSMA I&T?

Answer 3

Early completion of enrollment in initial staging trial

This indicates a quicker than expected progress in clinical trials.

Question 4

What is the reason for the extended development timeline of ISOPROTRACE?

Answer 4

Delay in anticipated NDA filing

NDA stands for New Drug Application, which is a request for approval of a new drug.

Question 5

What new agents were added to the prostate cancer PSMA-targeting and radiotherapeutics landscape?

Answer 5

CTT2274, 177Lu-P17-087, 177Lu-P17-088, 177Lu-AZ-093, 225Ac-FPI-1434, 225Ac-GRPR, 161Tb-SibuDAB, LNTH-2402, 177Lu-NeoB, 67Cu-NODAGA-PSMA-I&T, 212Pb-PSMA, 177Lu-OncoACP3, 177Lu-A70-B104-DOTA, RAD402, 161Tb-ART101, 225Ac-ART101

Added agents are from multiple companies including Cancer Targeted Technology, Five Eleven Pharma, Fusion Pharma, and others.

Question 6

Which agents were removed from the prostate cancer PSMA-targeting landscape?

Answer 6

AVC102, JNJ-80038114, CTT1700, LNTH-1558, LNTH-1095

These removals indicate a discontinuation or cessation of development for these agents.

Question 7

What caused the extended development timeline of TLX591?

Answer 7

Delayed US Phase 3 start

Phase 3 trials are crucial for assessing the efficacy of a drug before it can be approved.

Question 8

What is the expected timeline change for 225Ac-PSMA-617?

Answer 8

Reduced due to expected Phase 3 start in 2025

This indicates a more optimistic outlook for this agent’s progression.

Question 9

What change occurred to the development timeline of 177Lu-rhPMSA 10.1?

Answer 9

Reduced due to Phase 2 start in Q4 2024

This suggests a positive advancement in the clinical trial process.

Question 10

What new agents were added to the mCRPC landscape?

Answer 10

Talabostat, ciforadenant, patritumab deruxtecan, XNW5004, HRS-1167, INV-9956, SYNC-T SV-102, XmAb808

These agents are from various companies, indicating ongoing research in mCRPC treatments.

Question 11

Which agent was removed from the mCRPC landscape?

Answer 11

ARV-110

This indicates that the development of ARV-110 has been halted or discontinued.